Market Overview

Tickers

Articles

Keywords

cancer

Cancer. Research shows nearly every sixth death in the world is due to the disease, making it the second leading cause of death behind cardiovascular diseases.
The global pharmaceutical industry is estimated at an astounding $1.11 trillion in size. Every year, billions are spent on the...

An OTC-listed large-cap biotech is seeking a main exchange listing, and it offers scope for investing in a proven biotech with two commercial partnered products on the market and more in the pipeline.
The IPO Terms
Copenhagen, Denmark-based GENMAB A/S/S ADR (OTC: GMXAY) has filed for offering 27.80...

Shares of Johnson & Johnson (NYSE: JNJ) were trading lower Friday after Bloomberg reported that the Justice Department has launched a criminal probe into the company.
What Happened
The investigation is focused on whether J&J deceived the public about the risk of cancer linked to its...

The week will see the listing of a late entrant into the arena, but it nonetheless has an impressive pipeline of investigational assets targeting genetic diseases.
The IPO Terms
BridgeBio Pharma (NASDAQ: BBIO),founded in 2015 and headquartered in Palo Alto, California, is set to offer 15 million...

After a 10 percent drop Friday, Johnson & Johnson (NYSE: JNJ) opened Monday’s session down another 2 percent following last week’s Reuters report that the company has known about asbestos contamination in its baby powder for decades.
While the potential for legal and regulatory...

Agios Pharmaceuticals Inc (NASDAQ: AGIO), a pharmaceutical company that focuses on the field cellular metabolism to treat cancer and rare genetic diseases, is a stock investors should "own for the next several years," according to Piper Jaffray.
The Analyst
Piper Jaffray's Tyler M....

Ziopharm Oncology Inc. (NASDAQ: ZIOP) has two goals. One is to disrupt the narrative around recurrent glioblastomas. The other is to disrupt the entire pharmaceutical supply chain.
The latter pursuit isn’t just a B2B revenue opportunity, it's meant to alleviate cost barriers to critical...

NewLink Genetics Corp (NASDAQ: NLNK) said Friday it will review the clinical programs for its indoximod therapy after rival Incyte Corporation (NASDAQ: INCY) announced disappointing results from a study of the similar therapy epacadostat.
The Analyst
Baird Equity Research's Michael Ulz...

NewLink Genetics Corp (NASDAQ: NLNK), a late-stage biopharmaceutical company that focuses on cancer treatments, said on Friday it will review its clinical program after Merck & Co., Inc. (NYSE: MRK) and Incyte Corporation (NASDAQ: INCY) said their clinical trial of the similar drug epacadostat...

Incyte Corporation (NASDAQ: INCY), a biopharmaceutical company that focuses on developing medications for the treatment of cancer, announced Friday a disappointing update to a phase 3 trial.
What Happened
Incyte said its experimental therapy called epacadostat failed in a phase 3 trial called...